Miraca’s InformTx Treatment Response Platform for IBD Now Includes Testing for Inflectra

Miraca’s InformTx Treatment Response Platform for IBD Now Includes Testing for Inflectra
Miraca Life Sciences' InformTx testing helps doctors assess the response of patients with inflammatory bowel disease (IBD) to certain drug treatments. The company has now expanded its therapeutic drug monitoring (TDM) method by adding a test for Inflectra (infliximab). In the U.S., InformTx assesses drug and anti-drug antibody blood levels for the biologic drugs Cimzia (certolizumab pegol), Stelara (ustekinumab), Simponi (golimumab), Remicade (infliximab), Humira (adalimumab), and Entyvio (vedolizumab). Doctors will now be able to tell which patients respond well to the biosimilar Inflectra as a treatment for IBD. “The addition of a biosimilar drug to our InformTx therapeutic drug monitoring gives clinicians who treat IBD patients with the biosimilar Inflectra the same critical information as with other biologics,” Richard Lash, MD, Miraca Life Sciences’ chief medical officer and executive vice president of operations, said in a news release. “Understanding patients’ drug and anti-drug antibody status is critical to guiding optimal care.” InformTx uses enzyme-linked immunosorbent assay (ELISA) technology that provides quantitative test results, historical test result data, and guidance from current medical literature published in peer-reviewed scientific journals. The test requires small samples of peripheral blood, and results are available within five days. Patients respond differently to biologic drugs, and several parameters influence that response, such as inflammation, prior treatment with other dr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *